GlassScriptPhysician profile
Abbie Morgan
NPI 1093498305
$2,753.97
in general payments reported to CMS, 2019-2025
19 companies · $785 in 2025
The $785 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $159 · 2024: $1,809 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,737 · Education: $16.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.34 |
| Education | $16.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $632.42 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $376.48 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $317.73 | 2023-2025 | Entyvio, Eohilia |
| Abbvie INC. | $298.20 | 2023-2025 | |
| Ardelyx, INC. | $230.70 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $158.36 | 2023-2025 | Ocaliva |
| Gilead Sciences, INC. | $156.22 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $134.25 | 2023-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $124.98 | 2023-2025 | Voquezna |
| Genzyme Corporation | $100.84 | 2024-2025 | |
| Qol Medical, LLC | $50.65 | 2024-2025 | Sucraid, Sucraid |
| Atricure, INC. | $39.64 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $32.17 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $23.23 | 2024 | Iqirvo |
| Digestive Care, INC. | $18.63 | 2024 | Pertzye |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.53 | 2025 | |
| Myriad Genetic Laboratories, INC. | $15.33 | 2025 | Myrisk |
| Braintree Laboratories, INC. | $14.81 | 2023 | Sutab, Suflave |
| Amgen INC. | $13.80 | 2025 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbie Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.